|Articles|May 1, 2002
U.S. trial begins on hyperopic hydrogel intracorneal lens
Trois Rivieres, Quebec-Participants in a U.S. phase I clinical trial evaluating a hydrogel intracorneal lens (PermaVision, Anamed Inc., Lake Forest, CA) for the treatment of hyperopia should benefit from the changes implemented as a resultof previous international experience, said Francis Roy, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Looking back at the 2025 EnVision Summit
4
Last year in glaucoma at EnVision Summit 2025
5
























